by GlobeNewsWire | Dec 6, 2018 | Globe Newswire
SPRING, Texas, Dec. 06, 2018 (GLOBE NEWSWIRE) — GeoMet, Inc. (OTC: GMET; OTC: GMETP) (“GeoMet” or the “Company”) today announced its final distribution to the holders of its Series A Convertible Redeemable Preferred Stock, par value $0.001 per share (the...
by GlobeNewsWire | Dec 6, 2018 | Globe Newswire
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved...
by GlobeNewsWire | Dec 6, 2018 | Globe Newswire
Third Quarter 2018 Comparable Sales increased 4.8% Third Quarter 2018 Diluted Earnings Per Share Improved to $0.55 November 2018 Comparable Sales Increased 2.3% LYNNWOOD, Wash., Dec. 06, 2018 (GLOBE NEWSWIRE) — Zumiez Inc. (NASDAQ: ZUMZ) today reported results...
by GlobeNewsWire | Dec 6, 2018 | Globe Newswire
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) — Guggenheim Energy & Income Fund (the “Fund”) (XGEIX) announced today a tender offer to purchase for cash up to 2.5% of the Fund’s issued and outstanding common shares of beneficial interest (“common shares”). The...
by GlobeNewsWire | Dec 6, 2018 | Globe Newswire
SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced the appointment of...